Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is poised for strong financial performance, with an expected organic sales growth of 6.0-7.0% for 2025, supported by a robust 13.7% organic growth in its Electrophysiology business driven by recent product launches. The company also reported significant growth across its Diabetes (16.2%), Rhythm Management (13.0%), and Structural Heart (11.3%) segments, reflecting strong demand and market share gains in key therapeutic areas. Additionally, Abbott’s commitment to consistent dividend increases, maintained for over 50 consecutive years, underscores its solid financial health and potential for future value creation.

Bears say

Abbott Laboratories faces significant challenges impacting its financial outlook, particularly due to a sharp decline in Covid-19 testing-related sales, which fell to $69 million in Q3 2025 from $265 million in the previous year, indicating a persistent headwind. Additionally, macroeconomic pressures such as inflation and foreign exchange fluctuations are likely to exacerbate these challenges, contributing to lower-than-expected revenue across various segments, including Rapid Diagnostics. The impact of these factors, including underperformance in key product areas like CoreLab in China, has led to a mixed set of results, raising concerns about the company's ability to sustain organic revenue growth and profitability in the near term.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.